Risk factors for implant failure of custom-made acetabular implants in patients with Paprosky III acetabular bone loss and combined pelvic discontinuity.

Revision total hip arthroplasty acetabular bone loss aseptic loosening custom-made implant pelvic discontinuity periprosthetic joint infection risk factor treatment failure

Journal

Technology and health care : official journal of the European Society for Engineering and Medicine
ISSN: 1878-7401
Titre abrégé: Technol Health Care
Pays: Netherlands
ID NLM: 9314590

Informations de publication

Date de publication:
2022
Historique:
pubmed: 10 8 2021
medline: 3 6 2022
entrez: 9 8 2021
Statut: ppublish

Résumé

Severe acetabular bone loss in revision total hip arthroplasty (RTHA), both with or without pelvic discontinuity, remains a great challenge in orthopaedic surgery. The aim of this study was to evaluate risk factors for failure of custom-made acetabular implants in RTHA. Seventy patients with severe acetabular bone loss (Paprosky Type III) and pelvic discontinuity, who required RTHA, were included in our study. All prostheses were constructed based on a thin-layer computed-tomography (CT) scan of the pelvis. The treatment was considered unsuccessful in the event of periprosthetic joint infection (PJI) or aseptic loosening (AL) with need for explantation of the custom-made acetabular implant. The average follow-up was 41.9 ± 34.8 months (range 1.5-120). Implant survival at last follow-up was 75.7% (53 of 70). Explantation was necessary in 17 cases (15 PJI; 2 AL). Previous PJI as reason for RTHA (p= 0.025; OR 3.56 (95% CI: 1.14; 11.21)), additional revision of femoral components (p= 0.003; OR 8.4 (95% CI: 1.75; 40.42)), rheumatoid disease (p= 0.039; OR 3.43 (95% CI: 1.01; 11.40)), elevated preoperative CRP > 15.2 mg/l (p= 0.015; AUC: 0.7) and preoperative haemoglobin < 10.05 (p= 0.022; AUC: 0.69) were statistically significant risk factors associated with treatment failure. Age and BMI were not statistically significant contributing to implant failure. Risk factors for treatment failure were a previous PJI, additional revision of femoral component, rheumatoid disease, elevated preoperative CRP and low preoperative haemoglobin. Awareness of these risk factors will help to improve future treatment standards.

Sections du résumé

BACKGROUND BACKGROUND
Severe acetabular bone loss in revision total hip arthroplasty (RTHA), both with or without pelvic discontinuity, remains a great challenge in orthopaedic surgery.
OBJECTIVE OBJECTIVE
The aim of this study was to evaluate risk factors for failure of custom-made acetabular implants in RTHA.
METHODS METHODS
Seventy patients with severe acetabular bone loss (Paprosky Type III) and pelvic discontinuity, who required RTHA, were included in our study. All prostheses were constructed based on a thin-layer computed-tomography (CT) scan of the pelvis. The treatment was considered unsuccessful in the event of periprosthetic joint infection (PJI) or aseptic loosening (AL) with need for explantation of the custom-made acetabular implant.
RESULTS RESULTS
The average follow-up was 41.9 ± 34.8 months (range 1.5-120). Implant survival at last follow-up was 75.7% (53 of 70). Explantation was necessary in 17 cases (15 PJI; 2 AL). Previous PJI as reason for RTHA (p= 0.025; OR 3.56 (95% CI: 1.14; 11.21)), additional revision of femoral components (p= 0.003; OR 8.4 (95% CI: 1.75; 40.42)), rheumatoid disease (p= 0.039; OR 3.43 (95% CI: 1.01; 11.40)), elevated preoperative CRP > 15.2 mg/l (p= 0.015; AUC: 0.7) and preoperative haemoglobin < 10.05 (p= 0.022; AUC: 0.69) were statistically significant risk factors associated with treatment failure. Age and BMI were not statistically significant contributing to implant failure.
CONCLUSION CONCLUSIONS
Risk factors for treatment failure were a previous PJI, additional revision of femoral component, rheumatoid disease, elevated preoperative CRP and low preoperative haemoglobin. Awareness of these risk factors will help to improve future treatment standards.

Identifiants

pubmed: 34366301
pii: THC202236
doi: 10.3233/THC-202236
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

703-711

Auteurs

Frank S Fröschen (FS)

Department of Orthopaedic Surgery and Traumatology, University Hospital Bonn, Bonn, Germany.

Thomas M Randau (TM)

Department of Orthopaedic Surgery and Traumatology, University Hospital Bonn, Bonn, Germany.

Nadine Gravius (N)

Department of Orthopaedic Surgery and Traumatology, University Hospital Bonn, Bonn, Germany.

Dieter C Wirtz (DC)

Department of Orthopaedic Surgery and Traumatology, University Hospital Bonn, Bonn, Germany.

Sascha Gravius (S)

Department of Orthopaedic Surgery and Traumatology, University Hospital Mannheim, Mannheim, Germany.

Sebastian G Walter (SG)

Department of Orthopaedic Surgery and Traumatology, University Hospital Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH